JCB-JEM Symposium: Jedd Wolchok - Immunologic Checkpoint Blockade
9Jedd Wolchok gives his talk "Immunologic Checkpoint Blockade: Dissecting Mechanisms and Next Steps" as part of the JCB-JEM symposium on Tackling Cancer Plasticity and Heterogeneity at The Rockefeller University in New York, October 9th, 2018. https://rupress.org/pages/jcb-jem-symposium-tackling-cancer-plasticity-and-heterogeneity
The Wolchok lab at Memorial Sloan Kettering Cancer Center studies cancer immunotherapy.
Dr. Wolchok first gives a comprehensive overview of immunologic checkpoint blockade therapy for cancer. From numerous studies, we now know that mutational landscape fuels baseline immune reactivity. Primary immune evasion and adaptive resistance restrain therapeutic immunity. Checkpoint blockage may disinhibit baseline response to achieve regression and antigen spreading, leading to durable disease control in some patients. He then introduces some exciting stories from the lab, suggesting that adaptive immunity mobilizes innate cells to clear tumors but also promotes off-target side effects.
Video © Rockefeller University Press